Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene editing shot aims to permanently lower bad cholesterol

NCT ID NCT07839936

Disease control Sponsor: Verve Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 24, 2026 · Last updated Sep 25, 2026 · Updated 1 time

Summary

Researchers are testing a one-time gene editing medicine called VERVE-102 in adults who have plaque buildup in their arteries or are at high risk for it. The trial compares VERVE-102 to a placebo to see how much it lowers LDL cholesterol. About 175 people will receive either the medicine or the placebo through an IV. The goal is to find out if a single treatment can reduce the need for ongoing cholesterol-lowering drugs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VERVE-102, a one-time gene editing medicine given by IV
What this could lead to
If it works, a single IV treatment could lower bad cholesterol for years, possibly replacing daily pills or regular injections for people with inherited high cholesterol.
What could go wrong
This is a phase 2 trial, so researchers do not yet know if the gene editing is safe or effective. The body might not respond as hoped, or the effect could fade over time. Gene editing carries unknown long-term risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 175 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Established atherosclerotic cardiovascular disease (ASCVD) and/or at a high risk of ASCVD Exclusion Criteria: * History of confirmed or suspected homozygous familial hypercholesterolemia (HoFH) * Chronic liver disease * Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis atherosclerotic cardiovascular disease cardiovascular disorder coronary artery disorder Hypercholesterolemia hyperlipidemia myocardial infarction stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherosclerosis Cardiovascular disease Hypercholesterolemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Epic Medical Research

    DeSoto, Texas, 75115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.